CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 249 enrolled
Drug / intervention
infliximabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00230529
NCT00230529Phase 2Completed

A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Infliximab (REMICADE�) Induction Therapy in Patients With Plaque-type Psoriasis

Centocor, Inc.·interventional·Posted Oct 3, 2005·Updated Jun 9, 2011

In Brief

A Phase 2 clinical trial evaluating infliximab for Psoriasis. Completed, enrolled 249 participants.

Detailed Summary

The purpose of the study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with plaque-type psoriasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 3, 2005
Study CompletionJan 1, 2003
TodayJul 2, 2026
Posted 20.7 years ago

Interventions

infliximabdrug